Active substanceProstate extractProstate extract
Similar drugsTo uncover
  • Vitaprost®
    suppositories rect. 
    NIZHFARM, JSC     Russia
  • Prostatylene®
    suppositories rect. 
  • Prostatylene®
    lyophilizate w / m 
  • Prostatylene®
    suppositories rect. 
  • Samprost
    lyophilizate w / m 
    SAMSON-MED, LLC     Russia
  • Uroprost
    suppositories rect. 
    ALTFARM, LLC     Russia
  • Uroprost-D
    suppositories rect. 
    PATENT-FARM, CJSC     Russia
  • Dosage form: & nbsprectal suppositories
    Composition:For one suppository:

    Active substance: prostate extract - 30 mg (in terms of water-soluble peptides - 6 mg).

    Excipients: dimethylsulfoxide - 90 mg, macrogol 1500 (polyethylene oxide 1500) - 2180 mg.

    Description:

    Suppositories are translucent with possible marbling, almost colorless or with a yellowish or grayish tinge, torpedo-shaped. A slight softening of the surface layer and a "fogging" of the contour cell package is allowed. An air rod or a funnel-shaped depression is allowed.

    Pharmacotherapeutic group:Prostatitis is a chronic remedy
    ATX: & nbsp

    G.04.B.X   Other drugs for the treatment of urological diseases

    Pharmacodynamics:

    The drug has anti-inflammatory and anti-aggregation effect,stimulates the muscles of the bladder.

    The active substances of the extract of the prostate are referred to the group of peptide bioregulators - cytomedines. These drugs are peptides with a molecular weight of 1 to 10 kD. Low-molecular peptides of a para- or autocrine nature, perform the function of trans-specific intra- and intercellular messengers.

    Prostate gland peptides reduce clotting time and increase antiaggregatory activity of the vascular wall, improve blood microcirculation, increase fibrinolytic activity of the blood, increase the contractile activity of detrusor myocytes in vivo, in vitro.

    Have immunomodulatory and immunostimulating effect, enhance the synthesis of antihistamines and antiserotonin antibodies.

    The use of peptide bioregulators in the treatment of chronic prostatitis is the ability of these drugs to restore microcirculation, to have an indirect anti-inflammatory effect by enhancing the synthesis of antihistamine and antiserotonin antibodies, as well as their immunomodulating and immunostimulating effect.

    Treatment of benign prostatic hyperplasia is based on the most important biological effect of cytomedins: organotropicity, which allows to regulate the processes of differentiation and function of cells in the organ from which they are isolated.

    Pharmacokinetics:

    As a peptide drug, it is cleaved by cellular proteases up to amino acids. No cumulative effect.

    Indications:Chronic abacterial prostatitis, condition before and after operations on the prostate gland, benign prostatic hyperplasia.
    Contraindications:

    Individual intolerance (including hypersensitivity in anamnesis).

    Dosing and Administration:

    The drug is used rectally after defecation or cleansing enema. After moistening the suppository with water, inject it deep into the anus.

    Apply to 1 suppository 2 times a day (morning and evening). After the administration of the drug, it is desirable to stay in bed for 30-40 min.

    Duration of treatment - 5-10 days. According to the testimony, repeated courses are possible; it is recommended to hold no earlier than 2-4 weeks.

    Side effects:

    Often - 1-10%; sometimes 0.1-1%; rarely - 0,01-0,1%; very rarely - less than 0.01%, including individual cases.

    Very rarely - allergic reactions; often - itching in the anus; sometimes diarrhea, flatulence.

    Overdose:

    Currently, there have been no cases of overdose.

    Interaction:

    Negative interaction was not observed.

    The drug can be used for complex therapy.

    Special instructions:

    Treatment of chronic prostatitis should be complex, involving the use of different groups of drugs and non-drug therapies.

    In the treatment it is recommended to perform an analysis of the secretion of the prostate gland
    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles, mechanisms.

    Form release / dosage:

    Suppositories rectal, 6 mg.

    Packaging:

    For 5 suppositories in a contour cell box from a polyvinyl chloride film.

    Two contour mesh packages together with instructions for use in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date of the product indicated on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-004069
    Date of registration:10.01.2017
    Expiration Date:10.01.2022
    The owner of the registration certificate:PATENT-FARM, CJSC PATENT-FARM, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspPharmaceutical Technologies, LLCPharmaceutical Technologies, LLCRussia
    Information update date: & nbsp29.01.2017
    Illustrated instructions
      Instructions
      Up